174 related articles for article (PubMed ID: 25611896)
1. Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer.
AlHilli M; Langstraat C; Tran C; Martin J; Weaver A; McGree M; Mariani A; Cliby W; Bakkum-Gamez J
Int J Gynecol Cancer; 2015 Feb; 25(2):193-202. PubMed ID: 25611896
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.
Cham S; Chen L; St Clair CM; Hou JY; Tergas AI; Melamed A; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2019 Jun; 220(6):571.e1-571.e8. PubMed ID: 30771346
[TBL] [Abstract][Full Text] [Related]
3. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
Ross MS; Burriss ME; Winger DG; Edwards RP; Courtney-Brooks M; Boisen MM
Gynecol Oncol; 2018 Aug; 150(2):306-310. PubMed ID: 29929924
[TBL] [Abstract][Full Text] [Related]
4. Assessment of risk factors for 30-day hospital readmission after surgical cytoreduction in epithelial ovarian carcinoma.
Fauci JM; Schneider KE; Frederick PJ; Wilding G; Consiglio J; Sutton AL; Kilgore LC; Barnes MN
Int J Gynecol Cancer; 2011 Jul; 21(5):806-10. PubMed ID: 21412162
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
6. Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma.
Clark RM; Growdon WB; Wiechert A; Boruta D; Del Carmen M; Goodman AK; Bradford L; Rauh-Hain A; Schorge JO
Gynecol Oncol; 2013 Sep; 130(3):407-10. PubMed ID: 23747329
[TBL] [Abstract][Full Text] [Related]
7. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
[TBL] [Abstract][Full Text] [Related]
8. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
10. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
Clark RM; Rice LW; Del Carmen MG
Gynecol Oncol; 2018 Aug; 150(2):370-377. PubMed ID: 29929923
[TBL] [Abstract][Full Text] [Related]
11. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
Horowitz NS; Larry Maxwell G; Miller A; Hamilton CA; Rungruang B; Rodriguez N; Richard SD; Krivak TC; Fowler JM; Mutch DG; Van Le L; Lee RB; Argenta P; Bender D; Tewari KS; Gershenson D; Java JJ; Bookman MA
Gynecol Oncol; 2018 Jan; 148(1):49-55. PubMed ID: 29174555
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
13. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
14. Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
Uccella S; Mele MC; Quagliozzi L; Rinninella E; Nero C; Cappuccio S; Cintoni M; Gasbarrini A; Scambia G; Fagotti A
Gynecol Oncol; 2018 May; 149(2):263-269. PubMed ID: 29550182
[TBL] [Abstract][Full Text] [Related]
15. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer.
Ataseven B; Grimm C; Harter P; Heikaus S; Heitz F; Traut A; Prader S; Kahl A; Schneider S; Kurzeder C; du Bois A
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):834-840. PubMed ID: 27406097
[TBL] [Abstract][Full Text] [Related]
18. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
[TBL] [Abstract][Full Text] [Related]
19. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
